NCI’s CRDC Enables Cross-Domain Analysis of Large Data Sets
[case_player][/case_player] The National Cancer Institute has developed a cloud-based infrastructure, the Cancer Research Data...
Latest in Oncology
Complementary Blood and Tissue Molecular Testing for Newly Diagnosed NSCLC
Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer
Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation identification is essential to effective targeted therapies, Dr. Socinski suggests complementary...
Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center - James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved EGFR tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Compared to gefitinib, dacomitinib had...
Targeting RET-Fusion Mutations in NSCLC
Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer
Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion driver mutations are sometimes seen in NSCLC, particularly in patients with...
